Trinity Biotech Book Value Per Share Growth & History (TRIB)
Trinity Biotech's book value per share was -$0.19 for fiscal 2025.
View full Trinity Biotech company overviewTrinity Biotech annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.19 | -$0.09 | — |
| 2024 | 2024-12-31 | -$0.10 | $0.06 | — |
| 2023 | 2023-12-31 | -$0.16 | -$0.14 | — |
| 2022 | 2022-12-31 | -$0.01 | -$0.01 | — |
| 2021 | 2021-12-31 | -$0.00 | $0.02 | — |
| 2020 | 2020-12-31 | -$0.03 | -$0.08 | — |
| 2019 | 2019-12-31 | $0.06 | -$0.40 | −87.70% |
| 2018 | 2018-12-31 | $0.46 | -$0.22 | −32.43% |
| 2017 | 2017-12-31 | $0.68 | -$0.51 | −42.72% |
| 2016 | 2016-12-31 | $1.18 | -$1.13 | −48.73% |
| 2015 | 2015-12-31 | $2.31 | — | — |
Trinity Biotech quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | -$0.19 | -$0.09 | — |
| Q2 2025 | 2025-06-30 | -$0.13 | — | — |
| Q4 2024 | 2024-12-31 | -$0.10 | $0.06 | — |
| Q4 2023 | 2023-12-31 | -$0.16 | -$0.14 | — |
| Q4 2022 | 2022-12-31 | -$0.01 | -$0.01 | — |
| Q4 2021 | 2021-12-31 | -$0.00 | $0.02 | — |
| Q4 2020 | 2020-12-31 | -$0.03 | -$0.08 | — |
| Q4 2019 | 2019-12-31 | $0.06 | -$0.40 | −87.70% |
| Q4 2018 | 2018-12-31 | $0.46 | -$0.22 | −32.43% |
| Q2 2018 | 2018-06-30 | $3.19 | — | — |
| Q4 2017 | 2017-12-31 | $0.68 | — | — |
Trinity Biotech book value per share trends
Over the last five fiscal years, Trinity Biotech's book value per share decreased from -$0.03 to -$0.19, a change of -$0.17. The latest reported quarter, Q4 2025, shows -$0.19.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Trinity Biotech source filings ↗